Acute Dystonia by Droperidol during Intravenous Patient-Controlled Analgesia in Young Patients

Abstract

Patient-controlled analgesia (PCA) is an important means for postoperative analgesia with parenteral opioid. However, postoperative nausea and vomiting (PONV) remains a major problem with a PCA system. Droperidol is used in PCA to prevent PONV. Extrapyramidal reactions by droperidol are, however, occasionally induced. We describe two cases of severe extrapyramidal hypertonic syndrome with an intravenous administration of droperidol in PCA in young patients, following orthopedic surgery.

Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment

“… 26 Phenothiazines and butyrophenones have also been used in CINV, but their use, particularly when administered at a high dose, is limited by the risk of major extrapyramidal reactions (dystonia, parkinsonism and oculogyric crisis). 27 , 28 …”

“…26 Phenothiazines and butyrophenones have also been used in CINV, but their use, particularly when administered at a high dose, is limited by the risk of major extrapyramidal reactions (dystonia, parkinsonism and oculogyric crisis). 27,28 Antagonists of 5-hydroxytryptamine3 (5-HT3) receptors (ondansetron, granisetron, tropisetron, palonosetron) are used in CINV control. 29 Palonosetron is a second-generation 5-HT3 receptor antagonist that has been shown to achieve better control of emesis compared with ondansetron, in children receiving highly or moderately emetogenic chemotherapy over several days.…”

Disorders of Movement

“…13 Onset of dystonia may occur acutely or gradually, and the causes are heterogeneous (Table 46-2). 13 Onset of dystonia may occur acutely or gradually, and the causes are heterogeneous (Table 46-2).…”

Anesthetic management of emergency and planned endovideoscopic gynecological operations in the context of the COVID-19 novel coronavirus infection pandemic (review of the problem)

“…Они оправдались не в полной мере и неудовлетворенность качеством лечения ПОТР привела к поиску схем, дополняющих лечение апрепитантом, к выпуску комбинированных с ним препаратов [28,29,30]. Таким образом, проблема профилактики и лечения послеоперационной тошноты и рвоты и связанных с ними осложнений далека от разрешения [31,32,33,34]. Патогенез ПОТР сложен, и многие предрасполагающие факторы к его развитию имеют непосредственное отношение к обсуждаемой категории больных (женский пол, молодой возраст, высокое внутрибрюшное давление, постуральные реакции, послеоперационная тошнота и рвота в анамнезе).…”